Key Phase II and III clinical trials of fuzuloparib in China (sponsored by Jiangsu Hengrui Pharmaceuticals Co., Ltd.)
| Drug(s) | Indication | Phase | Status | Identifier |
|---|---|---|---|---|
| Ovarian cancers | ||||
| Fuzuloparib, placebo | Maintenance therapy in platinum-sensitive recurrent ovarian cancer after at least two previous lines of platinum-based chemotherapy and achieved either CR or PR to their most recent regimen | III | Active | NCT03863860 |
| Fuzuloparib, apatinib, placebo | Maintenance therapy in advanced ovarian cancer following response on first-line platinum-based chemotherapy | III | Recruiting | NCT04229615 |
| Fuzuloparib, apatinib | Advanced ovarian cancer following 2 or more platinum-containing regimens | II | Recruiting | NCT04517357 |
| Fuzuloparib | Platinum-sensitive, BRCA1/2-mutant recurrent ovarian cancer following 2 or more chemotherapy regimens | II | Active | NCT03509636 |
| Pancreatic cancers | ||||
| Fuzuloparib, placebo | Maintenance therapy in patients with gBRCA/PALB2-mutant metastatic pancreatic cancer whose disease has not progressed following first-line platinum-based chemotherapy | III | Recruiting | NCT04300114 |
| Fuzuloparib, placebo, mFOLFIRINOX | Combination therapy and subsequent maintenance therapy in advanced pancreatic cancer | I/II | Recruiting | NCT04228601 |
| Prostate cancers | ||||
| Fuzuloparib, placebo, abiraterone acetate and prednisone | First-line treatment in metastatic castration-resistant prostate cancer | III | Not yet recruiting | NCT04691804 |
| Fuzuloparib, abiraterone, apatinib, enzalutamine, prednisone | Metastatic castration-resistant prostate cancer in patients who failed prior treatment with abiraterone/enzalutamine and with or without homologous recombination repair gene mutations | II | Not yet recruiting | NCT04869488 |
| Fuzuloparib, rezvilutamide, placebo | Metastatic castration-resistant prostate cancer patients who did not respond to abiraterone and docetaxel treatment | II | Active | NCT04102124 |
| Breast cancers | ||||
| Fuzuloparib, apatinib, chemotherapy | HER2-negative metastatic breast cancer with germline BRCA mutation in patients who received no more than two lines of chemotherapy, received prior therapy with an anthracycline and a taxane and did not respond to one endocrine therapy or are not candidates for endocrine therapy | III | Recruiting | NCT04296370 |
| Lung cancers | ||||
| Fuzuloparib, adebrelimab, temozolomide | Relapsed small cell lung cancer in patients who failed one line of platinum-based chemotherapy | I/II | Recruiting | NCT04400188 |